Physician profile
Prathima Pabbathi
NPI 1740486349
$4,489.33
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $66.19 · 2021: $1,261 · 2022: $676 · 2023: $811 · 2024: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $850.35 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $418.89 | 2019-2024 | |
| Lilly USA, LLC | $384.33 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $301.42 | 2019-2024 | |
| Astellas Pharma US INC | $282.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $198.05 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Welch Allyn | $191.60 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.33 | 2021-2024 | Jardiance, Ofev |
| Sanofi-Aventis U.S. LLC | $139.54 | 2019 | |
| Amgen INC. | $127.47 | 2019-2024 | Otezla, Repatha, Prolia |
| Abbott Laboratories | $117.00 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $112.80 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $81.89 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $81.41 | 2019-2021 | |
| Amarin Pharma, INC. | $79.71 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prathima Pabbathi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.